Global Blood's sickle cell therapy heading for NDA

Global Blood Therapeutics Inc. (NASDAQ:GBT) added almost $800 million in market cap on Monday after it said FDA agreed with a proposed regulatory path by which the company could obtain accelerated approval of voxelotor (formerly GBT-440) to treat sickle cell disease. Global Blood hopes

Read the full 443 word article

User Sign In